Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
|
|
United Press International - December 30, 2004
Two groups of previously untreatable patients with HIV-1 subtype C were successfully treated with a combination of antiretroviral drugs that worked in patients with subtype B.
The first group also had tuberculosis and the second group had Kaposi's sarcoma, a form of cancer usually associated with skin lesions. HIV-1 subtype C, is rapidly spreading in developing countries where TB and KS are major causes of death among AIDS patients.
The TB group was treated with didanosine, lamivudine, and efavirenz. The KS group with stavudine, lamivudine, and nevirapine. After three months, 94 percent of the TB group and 80 percent of the Kaposi group had undetectable levels of the HIV virus -- rates equivalent to or better than those in studies involving Western patients infected with the B subtype.
The study is in the February1 issue of The Journal of Infectious Diseases. An editorial in the journal said the study proved that treatment success obtained in developed countries can be replicated in poorer settings and that patients in developing countries with opportunistic infections can benefit from antiretroviral therapy.
041230
UP041210
Copyright © 2004 - United Press International. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through United Press International, Permissions Desk, 1510 H St. N.W. Washington DC 2005. Main Phone Switchboard: 202-898-8000 FAX: 202-898-8057 or 202-898-8147 Email: info@upi.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .